Efficacy and limitations of repurposed drugs and vaccines for COVID-19-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and limitations of repurposed drugs and vaccines for COVID-19

Published:2024-04 Issue: Volume:2 Page:100041
ISSN:2949-916X
Container-title:Journal of Medicine, Surgery, and Public Health
language:en
Short-container-title:Journal of Medicine, Surgery, and Public Health

Author:

Murmu Nensina,Sarkar Mrinmoy,Dey Sananda,Manna Rahul,Roy Shreya,Mondal Tanushree,Halder Soma,Bhattacharjee Nandini,Dash Sandeep K.,Giri Biplab^ORCID

Publisher

Elsevier BV

Reference285 articles.

1. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update;Pal;Cureus,2020

2. SARS-CoV-2 and viral sepsis: immune dysfunction and implications in kidney failure;Stasi;J. Clin. Med,2020

3. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia;Li;N. Engl. J. Med.,2020

4. Therapeutic strategies for COVID-19: progress and lessons learned;Li;Nat. Rev. Drug Discov.,2023

5. Treatment options for COVID-19: The reality and challenges;Jean;J. Microbiol., Immunol. Infect.,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature;Saudi Journal of Biological Sciences;2024-07

2. Unravelling Insights into the Evolution and Management of SARS-CoV-2;BioMedInformatics;2024-02-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP